dpp 4 inhibitors vs glp 1 agonist Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Between 1969 and 1971, work by John Brown and Raymond Pederson, together with the peptide chemistry expertise of Erik Jorpes and Viktor Mutt [67], led to the identification of the gastric inhibitory polypeptide (GIP), a 42-amino acid polypeptide that was named based on its potency to suppress gastric motility and gastric acid secretion [[68], [69], [70]]
Understanding Retatrutide requires a breakdown of its tripartite action: 1
They also slow gastric emptying, creating prolonged fullness that reduces appetite and induces weight loss
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets
Pancreatic safety of once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus: Subgroup analysis by potential influencing factors
